<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Baragaña B</dc:creator>
  <dc:creator>Norcross NR</dc:creator>
  <dc:creator>Wilson C</dc:creator>
  <dc:creator>Porzelle A</dc:creator>
  <dc:creator>Hallyburton I</dc:creator>
  <dc:creator>Grimaldi R</dc:creator>
  <dc:creator>Osuna-Cabello M</dc:creator>
  <dc:creator>Norval S</dc:creator>
  <dc:creator>Riley J</dc:creator>
  <dc:creator>Stojanovski L</dc:creator>
  <dc:creator>Simeons FR</dc:creator>
  <dc:creator>Wyatt PG</dc:creator>
  <dc:creator>Delves MJ</dc:creator>
  <dc:creator>Meister S</dc:creator>
  <dc:creator>Duffy S</dc:creator>
  <dc:creator>Avery VM</dc:creator>
  <dc:creator>Winzeler EA</dc:creator>
  <dc:creator>Sinden RE</dc:creator>
  <dc:creator>Wittlin S</dc:creator>
  <dc:creator>Frearson JA</dc:creator>
  <dc:creator>Gray DW</dc:creator>
  <dc:creator>Fairlamb AH</dc:creator>
  <dc:creator>Waterson D</dc:creator>
  <dc:creator>Campbell SF</dc:creator>
  <dc:creator>Willis P</dc:creator>
  <dc:creator>Read KD</dc:creator>
  <dc:creator>Gilbert IH</dc:creator>
  <dc:date>2016</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/51272</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1021/acs.jmedchem.6b00723</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27631715</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Journal of medicinal chemistry. - 2016</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Antimalarials</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Disease Models, Animal</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Drug Discovery</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Malaria</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Mice</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Molecular Structure</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Plasmodium falciparum</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Quinolines</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Structure-Activity Relationship</dc:subject>
  <dc:title xmlns:ns11="xml" ns11:lang="en">Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
